Investigational drug · Phase 2
NBI-1065890
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Tardive Dyskinesia.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "NBI-1065890"
First trial start
2026
Feb 6, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NBI-1065890", any sponsor or status.
Conditions studied
As listed on its trial records.
- Tardive Dyskinesia
Approved drugs for the same conditions: Tardive dyskinesia · Neurology · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "NBI-1065890" as an intervention, largest first.
- Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive DyskinesiaPivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07365462 · 100 participants (planned) · Start Feb 6, 2026 · Primary completion Feb 2027
Drug: NBI-1065890; Placebo · For: Tardive Dyskinesia
Sites: Bryant, Arkansas; Chino, California; Fountain Valley, California · 48 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Neurocrine Biosciences.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.